KYOTO – Nobel Prize-winning Japanese scientist Tasuku Honjo stopped in over the weekend at a Kyoto barbershop he has been visiting for over half a century as he prepares for his trip to Stockholm next week for the award ceremony. On Sunday, the 76-year-old, who won this year's Nobel Prize in physiology or medicine along with American James Allison for their studies on cancer therapy, was seen at the shop in Kyoto chatting with his 81-year-old longtime barber. "Hey, your hands are shaky. Haven't you ever thought of retiring?" the professor emeritus at Kyoto University asked barber Koichi Ueda, who works with his son at the Biriken barber shop near the university. "He was the kind of student who did not hesitate to speak up about his opinions," Ueda said about his impression of Honjo back when he first came to the shop Their discussions while Honjo was in the barber's chair ranged from the student uprisings of the 1970s to baseball.
STOCKHOLM – Japanese scientist Tasuku Honjo was awarded on Monday this year's Nobel Prize in physiology or medicine, for his discovery of a protein that contributed to the development of an immunotherapeutic drug against cancer. Honjo, a 76-year-old professor at Kyoto University, won the prize with U.S. national James Allison, the Nobel Assembly at the Karolinska Institute said. Honjo opened a pathway for a new cancer treatment by discovering the PD-1 protein, which is responsible for suppressing immune response. "I'm very honored and pleased to receive the Nobel Prize in physiology or medicine," Honjo told a news conference following the announcement. His method of treating cancer -- by controlling the protein's function to suppress immunity -- led to the development of Nivolumab, a drug marketed as Opdivo and used against lung cancer and melanoma.
STOCKHOLM – Japanese scientist Tasuku Honjo, who jointly won this year's Nobel Prize in physiology or medicine for his research on the immune system that contributed to cancer treatments, said Thursday that he believes most cancers will become treatable with immunotherapy by 2050. The 76-year-old professor and deputy director-general at the Kyoto University Institute for Advanced Study spoke at a news conference at the Karolinska Institute in Stockholm, joined by American scientist James Allison, who shared the prize. The discovery by Honjo and Allison -- on methods to inhibit negative immune regulation -- established a new principle for cancer treatment that stimulates the inherent ability of the human immune system to unleash attacks on tumor cells, according to the Nobel Assembly. Honjo said it may become possible to contain the growth of most cancer cells through such treatment, even if cancer cannot be completely eliminated, as he discussed the effectiveness of combination therapy using drugs in the development of which he and Allison were involved. The Kyoto native and his team discovered PD-1, a protein on immune cells that operates as a brake on the immune system.
Nobel laureate and immunologist Tasuku Honjo on Tuesday called for a better environment in Japan for conducting research in the life sciences, saying more efforts are needed by both the private and public sectors in enabling researchers to come up with medical cures for illnesses such as cancer. The Kyoto University professor, who was awarded this year's Nobel Prize in medicine for his studies on cancer therapy that focus on controlling the immune system, told a meeting of ruling lawmakers at the Liberal Democratic Party headquarters in Tokyo about difficulties in the process that led to the development of the immunotherapeutic drug Opdivo. He spoke of his partnership with a Japanese pharmaceutical firm that didn't always work, his cooperation with a U.S. company that led to clinical trials for the drug and his recollection that the favorable results of the tests that came out in 2012 were not covered by the Japanese media. "Researchers around the world were surprised by the results because at the time people didn't think immunotherapy was effective in treating cancer," Honjo said. "Most of the patients who took part in the clinical trials were terminal cancer patients and the drug was effective for 20 to 30 percent of those patients. In addition, the effect continued even after administering of the medicine was stopped after half a year," he said.